A single-chain IL-12 IgG3 antibody fusion protein retains antibody specificity and IL-12 bioactivity and demonstrates antitumor activity

Journal of Immunology

Volumn 163, Issue 1, 1999, Pages 250-258

  Peng, Lisan S ^a   Penichet, Manuel L ^a   Morrison, Sherie L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYBRID PROTEIN; IMMUNOGLOBULIN G ANTIBODY; INTERLEUKIN 12; INTERLEUKIN 12 RECEPTOR; ONCOPROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY SPECIFICITY; ANTIGEN BINDING; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CELL PROLIFERATION; COLON ADENOCARCINOMA; CONTROLLED STUDY; DRUG DESIGN; DRUG EFFICACY; DRUG POTENCY; DRUG RECEPTOR BINDING; FEMALE; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; MONONUCLEAR CELL; MOUSE; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN STABILITY; TUMOR VOLUME;

EID: 0033168121     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.163.1.250     Document Type: Article

References (53)

1. Rosenberg, S. A., P. J. Spiess, and S. Schwarz. 1983. In vivo administration of interleukin-2 enhances specific alloimmune responses. Transplantation 35:631.
2. Nastala, C. L., H. D. Edington, T. G. McKinney, H. Tahara, M. A. Nalesnik, M. J. Brunda, M. K. Gately, S. F. Wolf, R. D. Schreiber, W. J. Storkus, and et al. 1994. Recombinant IL-12 administration induces tumor regression in association with IFN-γ production. J. Immunol. 153:1697.
3. Rosenberg, S. A., J. C. Yang, D. E. White, and S. M. Steinberg. 1998. Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response. Ann. Surg. 228:307.
4. Tsung, K., J. B. Meko, G. R. Peplinski, Y. L. Tsung, and J. A. Norton. 1997. IL-12 induces T helper 1-directed antitumor response. J. Immunol. 158:3359.
5. Motzer, R. J., A. Rakhit, L. H. Schwartz, T. Olencki, T. M. Malone, K. Sandstrom, R. Nadeau, H. Parmar, and R. Bukowski. 1998. Phase I trial of subcutaneous recombinant human interleukin-12 in patients with advanced renal cell carcinoma. Clin. Cancer Res. 4:1183.
6. Royal, R. E., S. M. Steinberg, R. S. Krouse, G. Heywood, D. E. White, P. Hwu, F. M. Marincola, D. R. Parkinson, D. J. Schwartzentruber, S. L. Topalian, J. C. Yang, and S. A. Rosenberg. 1996. Correlates of response to IL-2 therapy in patients treated for melastatic renal cancer and melanoma. Cancer J. Sci. Am. 2:91.
7. Hurford, R. K., Jr., G. Dranoff, R. C. Mulligan, and R. I. Tepper. 1995. Gene therapy of metastatic cancer by in vivo retroviral gene targeting. Nat. Genet. 10:430.
8. Gold, P., and S. O. Freedman. 1965. Demonstration of tumor-specific antigens in the human colonic carcinomata by immunological tolerance and absorption techniques. J. Exp. Med. 121:439.
9. Waldmann, T. A. 1987. The role of the multichain IL-2 receptor complex in the control of normal and malignant T-cell proliferation. Environ. Health Perspect. 75:11.
10. Trowbridge, I. S., and F. Lopez. 1982. Monoclonal Ab to transferrin receptor blocks transferrin binding and inhibits human tumor cell growth in vitro. Proc. Natl. Acad. Sci. USA 79:1175.
11. Little, C. D., M. M. Nau, D. N. Carney, A. F. Gazdar, and J. D. Minna. 1983. Amplification and expression of the c-myc oncogene in human lung cancer cell lines. Nature 306:194.
12. Stevenson, G. T., and F. K. Stevenson. 1975. Ab to a molecularly defined antigen confined to a tumour cell surface. Nature 254:714.
13. Senba, T., M. Kuroki, F. Arakawa, T. Yamamoto, M. Kuwahara, M. Haruno, S. Ikeda, and Y. Matsuoka. 1998. Tumor growth suppression by a mouse/human chimeric anti-CEA Ab and lymphokine-activated killer cells in vitro and in SCID mouse xenograft model. Anticancer Res. 18:17.
14. Waldmann, T. A. 1994. Anti-IL-2 receptor monoclonal Ab (anti-Tac) treatment of T-cell lymphoma. Important Adv. Oncol. 131.
15. Kemp, J. D., K. M. Smith, J. M. Mayer, F. Gomez, J. A. Thorson, and P. W. Naumann. 1992. Effects of anti-transferrin receptor Abs on the growth of neoplastic cells. Pathobiology 60:27.
16. Robinson-Benion, C., K. E. Salhany, S. R. Hann, and J. T. Holt. 1991. Antisense inhibition of c-myc expression reveals common and distinct mechanisms of growth inhibition by TGF β and TNF α. J. Cell. Biochem. 45:188.
17. Hsu, F. J., C. B. Caspar, D. Czerwinski, L. W. Kwak, T. M. Liles, A. Syrengelas, B. Taidi-Laskowski, and R. Levy. 1997. Tumor-specific idiotype vaccines in the treatment of patients with B- cell lymphoma-long-term results of a clinical trial. Blood 89:3129.
18. Slamon, D. J., G. M. Clark, S. G. Wong, W. J. Levin, A. Ullrich, and W. L. McGuire. 1987. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177.
19. Slamon, D. J., W. Godolphin, L. A. Jones, J. A. Holt, S. G. Wong, D. E. Keith, W. J. Levin, S. G. Stuart, J. Udove, A. Ullrich, et al. 1989. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707.
20. Baselga, J., D. Tripathy, J. Mendelsohn, S. Baughman, C. C. Benz, L. Dantis, N. T. Sklarin, A. D. Seidman, C. A. Hudis, J. Moore, P. P. Rosen, T. Twaddell, I. C. Henderson, and L. Norton. 1996. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal Ab in patients with HER2/neu-overexpressing metastatic breast cancer. J. Clin. Oncol. 14:737.
21. Talmadge, J. E., H. Phillips, J. Schindler, H. Tribble, and R. Pennington. 1987. Systematic preclinical study on the therapeutic properties of recombinant human interleukin 2 for the treatment of metastatic disease. Cancer Res. 47:5725.
22. Becker, J. C., N. Varki, S. D. Gillies, K. Furukawa, and R. A. Reisfeld. 1996. Long-lived and transferable tumor immunity in mice after targeted interleukin-2 therapy. J. Clin. Invest. 98:2801.
23. Harvill, E. T., and S. L. Morrison. 1995. An IgG3-IL2 fusion protein activates complement, binds FcγRI, generates LAK activity and shows enhanced binding to the high affinity IL-2R. Immunotechnology 1:95.
24. Harvill, E. T., J. M. Fleming, and S. L. Morrison. 1996. In vivo properties of an IgG3-IL-2 fusion protein: a general strategy for immune potentiation. J. Immunol. 157:3165.
25. Lode, H. N., R. Xiang, N. M. Varki, C. S. Dolman, S. D. Gillies, and R. A. Reisfeld. 1997. Targeted interleukin-2 therapy for spontaneous neuroblastoma metastases to bone marrow. J. Natl. Cancer Inst. 89:1586.
26. Lode, H. N., R. Xiang, T. Dreier, N. M. Varki, S. D. Gillies, and R. A. Reisfeld. 1998. Natural killer cell-mediated eradication of neuroblastoma metastases to bone marrow by targeted interleukin-2 therapy. Blood 91:1706.
27. Penichet, M. L., E. T. Harvill, and S. L. Morrison. 1997. Ab-IL-2 fusion proteins: a novel strategy for immune protection. Human Abs 8:106.
28. Hendrzak, J. A., and M. J. Brunda. 1996. Antitumor and antimetastatic activity of interleukin-12. Curr. Top. Microbiol. Immunol. 213:65.
29. Trinchieri, G. 1998. Immunobiology of interleukin-12. Immunol. Res. 17:269.
30. Voest, E. E., B. M. Kenyon, M. S. O'Reilly, G. Truitt, R. J. D'Amato, and J. Folkman. 1995. Inhibition of angiogenesis in vivo by interleukin 12. J. Natl. Cancer Inst. 87:581.
31. Gubler, U., A. O. Chua, D. S. Schoenhaut, C. M. Dwyer, W. McComas, R. Motyka, N. Nabavi, A. G. Wolitzky, P. M. Quinn, P. C. Familletti, et al. 1991. Coexpression of two distinct genes is required to generate secreted bioactive cytotoxic lymphocyte maturation factor. Proc. Natl. Acad. Sci. USA 88:4143.
32. Gillies, S. D., Y. Lan, J. S. Wesolowski, X. Qian, R. A. Reisfeld, S. Holden, M. Super, and K.-M. Lo. 1998. Ab-IL-12 fusion proteins are effective in SCID mouse models of prostate and colon carcinoma metastases. J. Immunol. 160:6195.
33. Penichet, M. L., P.-M. Challita, S.-U. Shin, S. L. Sampogna, J. D. Rosenblatt, and S. L. Morrison. 1999. In vivo properties of three human HER2/neu expressing murine cell lines in immunocompetent mice. Lab. Anim. Sci. 49:179.
34. Carter, P., L. Presta, C. M. German, J. B. Ridgway, D. Henner, W. L. Wong, A. M. Rowland, C. Kotts, M. E. Carver, and H. M. Shepard. 1992. Humanization of an anti-p185HER2 Ab for human cancer therapy. Proc. Natl. Acad. Sci. USA 89:4285.
35. 2 fragment for improved binding to T cells. Int. J. Cancer Suppl. 7:45.
36. Challita-Eid, P. M., M. L. Penichet, S. U. Shin, T. Poles, N. Mosammaparast, K. Mahmood, D. J. Slamon, S. L. Morrison, and J. D. Rosenblatt. 1998. AB7.1-Ab fusion protein retains Ab specificity and ability to activate via the T cell costimulatory pathway. J. Immunol. 160:3419.
37. Huston, J. S., D. Levinson, M. Mudgett-Hunter, M. S. Tai, J. Novotný, M. N. Margolies, R. J. Ridge, R. E. Bruccoleri, E. Haber, R. Crea, et al. 1988. Protein engineering of Ab binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli. Proc. Natl. Acad. Sci. USA 85:5879.
38. Coloma, M. J., A. Hastings, L. A. Wims, and S. L. Morrison. 1992. Novel vectors for the expression of Ab molecules using variable regions generated by polymerase chain reaction. J. Immunol. Methods 152:89.
39. Shin, S. U., and S. L. Morrison. 1990. Expression and characterization of an Ab binding specificity joined to insulin-like growth factor 1: potential applications for cellular targeting. Proc. Natl. Acad. Sci. USA 87:5322.
40. Desai, B. B., T. Truit, S. Honasoge, R. Warrier, R. Chizzonite, and M. Gately. 1993. Expression of functional IL-12 receptor on a human IL-2 dependent T cell line. J. Immunol. 150:207A.
41. Chizzonite, R., T. Truitt, B. B. Desai, P. Nunes, F. J. Podlaski, A. S. Stern, and M. K. Gately. 1992. IL-12 receptor. I. Characterization of the receptor on phytohemagglutinin-activated human lymphoblasts. J. Immunol. 148:3117.
42. Gately, M. K., R. Chizzonite, and D. H. Presky. 1995. Measurement of human and mouse interleukin-12. In Current Protocols in Immunology, Vol. 1. J. E. Coligan, A. M. Kruisbeek, D. H. Margulies, E. M. Shevach, and W. Strober, eds. John Wiley & Sons, New York, p. 6.16.1.
43. Hatam, L., S. Schuval, and V. R. Bonagura. 1994. Flow cytometric analysis of natural killer cell function as a clinical assay. Cytometry 16:59.
44. Schoenhaut, D. S., A. O. Chua, A. G. Wolitzky, P. M. Quinn, C. M. Dwyer, W. McComas, P. C. Familletti, M. K. Gately, and U. Gubler. 1992. Cloning and expression of murine IL-12. J. Immunol. 148:3433.
45. Lieschke, G. J., P. K. Rao, M. K. Gately, and R. C. Mulligan. 1997. Bioactive murine and human interleukin-12 fusion proteins which retain antitumor activity in vivo. Nat. Biotechnol. 15:35.
46. Lode, H. N., T. Dreier, R. Xiang, N. M. Varki, A. S. Kang, and R. A. Reisfeld. 1998. Gene therapy with a single chain interleukin 12 fusion protein induces T cell-dependent protective immunity in a syngeneic model of murine neuroblastoma. Proc. Natl. Acad. Sci. USA 95:2475.
47. Anderson, R., I. MacDonald, T. Corbet, G. Hacking, M. W. Lowdell, and H. G. Prentice. 1997. Construction and biological characterization of an interleukin-12 fusion protein (Flexi-12): delivery to acute myeloid leukemic blasts using adeno-associated virus. Hum. Gene Ther. 8:1125.
48. Kim, T. S., R. H. DeKruyff, R. Rupper, H. T. Maecker, S. Levy, and D. T. Umetsu. 1997. An ovalbumin-IL-12 fusion protein is more effective than ovalbumin plus free recombinant IL-12 in inducing a T helper cell type 1-dominated immune response and inhibiting antigen-specific IgE production. J. Immunol. 158:4137.
49. Wu, C. Y., R. R. Warrier, D. M. Carvajal, A. O. Chua, L. J. Minetti, R. Chizzonite, P. K. Mongini, A. S. Stern, U. Gubler, D. H. Presky, and M. K. Gately. 1996. Biological function and distribution of human interleukin-12 receptor β chain. Eur. J. Immunol. 26:345.
50. Presky, D. H., L. J. Minetti, S. Gillessen, V. L. Wilkinson, C. Y. Wu, U. Gubler, R. Chizzonite, and M. K. Gately. 1998. Analysis of the multiple interactions between IL-12 and the high affinity IL-12 receptor complex. J. Immunol. 160: 2174.
51. McGrath, J. P., X. Cao, A. Schutz, P. Lynch, T. Ebendal, M. J. Coloma, S. L. Morrison, and S. D. Putney. 1997. Bifunctional fusion between nerve growth factor and a transferrin receptor Ab. J. Neurosci. Res. 47:123.
52. Zou, J. P., N. Yamamoto, T. Fujii, H. Takenaka, M. Kobayashi, S. H. Herrmann, S. F. Wolf, H. Fujiwara, and T. Hamaoka. 1995. Systemic administration of rIL-12 induces complete tumor regression and protective immunity: response is correlated with a striking reversal of suppressed IFN-γ production by anti-tumor T cells. Int. Immunol. 7:1135.
53. Zitvogel, L., H. Tahara, P. D. Robbins, W. J. Storkus, M. R. Clarke, M. A. Nalesnik, and M. T. Lotze. 1995. Cancer immunotherapy of established tumors with IL-12: effective delivery by genetically engineered fibroblasts. J. Immunol. 155:1393.